Abstract
Objective The present study was aimed at a comprehensive analysis of acquired thrombophilia in a large series of Indian women with fetal loss. Study design Four hundred and thirty women (median age 26 years, range 18–39 years) with unexplained fetal loss (median number of abortions 3, range 1–13) were screened for the presence of antiphospholipid antibodies (APA), i.e. lupus anticoagulant (LA), IgG/M antibodies for cardiolipin (ACA), β2 glycoprotein 1 (β2 GP1) and annexin V. We also studied 100 normal healthy women (median age 24 years, range 18–30 years) who had at least one healthy child and did not have any miscarriage or other obstetric complications. Results The prevalence of persistently positive LA was 8.1% and 1% in the patients and controls, respectively (OR 8.7; 95% CI, 1.4–51; P < 0.05). The overall prevalence of IgG and/or IgM antibodies for cardiolipin, β2 GP1 and annexin V were as follows—ACA 27.9% (OR 18.9; 95% CI, 5–70; P < 0.05), β2 GP1 12.2% (OR 6.8; 95% CI, 1.8–25; P < 0.05) and annexin V 14.6% (OR 17; 95% CI, 2.9–98; P < 0.05). The conventional LA and ACA tests were positive 23.2% of the cases as against 1% in the controls (OR 14.8; 95% CI, 3.9–55; P < 0.05). The prevalence of LA, ACA, β2 GP1 and annexin V antibodies as independent risk factors were observed in 0.5%, 16.5%, 5.4% and 7.8% in the patients as against 1% each in the controls. The overall positivity for any one of the APA studied was 42.6% (OR 10.2; 95% CI, 4.5–23; P < 0.05). Conclusion The present study thus indicates the importance of APA in women experiencing fetal loss where all the conventional causes of miscarriages have been ruled out. It also suggests that conventional APA assays (LA and ACA) are effective in the detection of a majority of APA positive cases and by the addition of other cofactor-dependent (β2 GP1 and annexin V) APA assays, there is a considerable increase in the diagnostic efficiency in the detection of APA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: European Journal of Obstetrics & Gynecology and Reproductive Biology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.